11β-Hydroxysteroid Dehydrogenase Type 1, But Not Type 2, Deficiency Worsens Acute Inflammation and Experimental Arthritis in Mice

Agnes E. Coutinho, Mohini Gray, David G. Brownstein, Donald M. Salter, Deborah A. Sawatzky, Spike Clay, James S. Gilmour, Jonathan R. Seckl, John S. Savill, and Karen E. Chapman

Centre for Cardiovascular Sciences (A.E.C., J.S.G., J.R.S., K.E.C.), Centre for Inflammation Research (A.E.C., M.G., D.M.S., D.A.S., S.C., J.S.G., J.S.S.), and Mouse Pathology Core Laboratory (D.G.B.), Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom

Glucocorticoids profoundly influence immune responses, and synthetic glucocorticoids are widely used clinically for their potent antiinflammatory effects. Endogenous glucocorticoid action is modulated by the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). In vivo, 11β-HSD1 catalyzes the reduction of inactive cortisone or 11-dehydrocorticosterone into active cortisol or corticosterone, respectively, thereby increasing intracellular glucocorticoid levels. 11β-HSD2 catalyzes the reverse reaction, inactivating intracellular glucocorticoids. Both enzymes have been postulated to modulate inflammatory responses. In the K/BxN serum transfer model of arthritis, 11β-HSD1-deficient mice showed earlier onset and slower resolution of inflammation than wild-type controls, with greater exostoses in periarticular bone and, uniquely, ganglion cysts, consistent with greater inflammation. In contrast, K/BxN serum arthritis was unaffected by 11β-HSD2 deficiency. In a distinct model of inflammation, thioglycollate-induced sterile peritonitis, 11β-HSD1-deficient mice had more inflammatory cells in the peritoneum, but again 11β-HSD2-deficient mice did not differ from controls. Additionally, compared with control mice, 11β-HSD1-deficient mice showed greater numbers of inflammatory cells in pleural lavages in carrageenan-induced pleurisy with lung pathology consistent with slower resolution. These data suggest that 11β-HSD1 limits acute inflammation. In contrast, 11β-HSD2 plays no role in acute inflammatory responses in mice. Regulation of local 11β-HSD1 expression and/or delivery of substrate may afford a novel approach for antiinflammatory therapy. (Endocrinology 153: 234–240, 2012)
fibroblasts of patients with rheumatoid arthritis and is highly induced by the proinflammatory cytokines IL-1 and TNF-α in the latter cell type (13). Moreover, 11β-HSD1 is induced in cells recruited into the peritoneum during sterile peritonitis (9) and is increased in intestine in both human and rodent colitis (14, 15). Macrophages from mice deficient in 11β-HSD1 show delayed acquisition of phagocytic capacity and exaggerated production of IL-6 and other cytokines after activation with lipopolysaccharide (9, 16).

Although 11β-HSD2 is not normally expressed in immune cells in either humans or mice (7, 9), 11β-HSD2 has been reported in immune cells in joints of patients with rheumatoid arthritis (12, 17). The nonselective 11β-HSD inhibitor, glycyrrhetinic acid, exerts antiinflammatory activity in rheumatoid arthritis, an effect interpreted as due to 11β-HSD2 inhibition (18). Reciprocal regulation of 11β-HSD1 and 11β-HSD2 by IL-1 and TNF-α has been reported in several nonimmune tissues (19, 20). It has therefore been suggested that targeting 11β-HSD2 may be an effective treatment in rheumatoid arthritis. However, the effects of 11β-HSD2 deficiency on inflammatory responses have not been reported. Moreover, 11β-HSD1 inhibitors are in clinical trials for metabolic disease and understanding the role of 11β-HSD in arthritis and other clinically relevant inflammatory conditions may be critical to their exploitation.

A rheumatoid arthritis-like disease develops spontaneously in offspring of KRN-transgenic mice bred with NOD mice due to circulating anti-glucose-6-phosphate-isomerase autoantibodies (K/BxN serum) (21). Injection of K/BxN serum into naive mice reliably and reproducibly induces a self-resolving passive arthritis in recipient mice (22). Here we have used mice deficient in either 11β-HSD1 (23) or 11β-HSD2 (24) to investigate the role of these enzymes in K/BxN serum-induced inflammatory arthritis and other mouse models of inflammation.

Materials and Methods

Animals

Mice homozygous for a targeted disruption of the Hsd11b1 gene (Hsd11b1<sup>−/−</sup>) or the Hsd11b2 gene (Hsd11b2<sup>−/−</sup>), both congenic on the C57BL/6J background (more than eight backcrosses), have been previously described (23–25). Controls were age-matched C57BL/6J mice. All experimental mice were males, aged 8–12 wk, housed in groups of two to five mice per cage under controlled conditions (12 h light, 12 h dark cycle, 21 C) with ad libitum access to water and standard rodent chow. All experimentation was conducted in strict accord with accepted standards of humane animal care under the auspices of the U.K. Animals (Scientific Procedures) Act, 1986, after the prior approval by the local ethical committee.


FIG. 1. 11β-HSD1 deficiency worsens arthritis in mice. K/BxN arthritis was induced in Hsd11b1<sup>−/−</sup> (white squares, white bar) and control mice (black squares, black bar) by ip injection of arthritogenic K/BxN serum, using a standard dose of 7.5 μl/g body weight on d 0 and d 2 (A) and a reduced dose of 5.6 μl/g body weight on d 0 only (B). Clinical score (based on edema and redness of carpal and hock joints) was measured over 21 d. Insets show AUC. Data are mean ± SD (n = 5/group), P < 0.05 by repeated-measures ANOVA or (for AUC) by unpaired Student’s t test. *, P < 0.05.

FIG. 2. 11β-HSD2-deficiency has no effect on K/BxN arthritis in mice. K/BxN arthritis was induced in Hsd11b2<sup>−/−</sup> (white squares, white bar) and control mice (black squares, black bar) by a single ip injection of arthritogenic K/BxN serum (5.6 μl/g body weight) on d 0. Clinical score was measured over 21 d. Inset shows AUC. Data are mean ± SD (n = 5–8/group); P = 0.96 by repeated-measures ANOVA or (for AUC) by unpaired Student’s t test; P = 0.69.
receptor KRN and the MHC class II allele A^*^ as previously described (26) using either the standard dose (7.5 μl/g of body weight on d 0 and d 2) or a reduced dose (single injection of 5.6 μl/g of body weight on d 0). The standard dose produces a maximal response in control mice; thus, the reduced dose was used to test the hypothesis that the inflammatory response would be greater in Hsd11b1^−/−^ mice. Inflammation was scored by visual examination according to a clinical index in which each joint was assigned a score of 0–3 as described (38). The mean cumulative scores were calculated (maximum score per animal of 12) for each group. Right tarsal joint swelling was measured using a caliper (Kroepelin POCO-2T; Wessex Metrology, Poole, UK) and was defined as the cumulative difference in joint diameter (millimeters) after induction of arthritis from that measured at the start of the experiment, reported as mean area under the curve (AUC) per group. For histology, joints were fixed in 10% formalin, decalcified in 10% EDTA in neutral buffered formalin, and paraffin embedded. Deparaffinized and hydrated joint sections (4 μm) were stained with hematoxylin and eosin for histopathological examination.

**Corticosterone RIA**

Peripheral blood was collected from Hsd11b1^−/−^ and wild-type mice 2 d and 21 d after induction of K/BxN arthritis under nonstressed conditions by tail nick at 0800 h for measurement of circulating corticosterone by RIA as described previously (27).

**Thioglycollate-induced sterile peritonitis**

Peritonitis was induced in mice by ip injection of 1 ml of 3% thioglycollate as previously described (9). Peritoneal cells were collected by lavage with 5 ml cold PBS and counted by hemocytometer.

**Carrageenan-induced pleurisy**

Pleural inflammation was induced in mice by intrapleural injection of 100 μl of 0.1% λ-carrageenan (Marine Colloids Inc., FMC BioPolymer, Philadelphia, PA) as previously described (28). The pleural exudates were collected by lavage with 1 ml cold PBS containing 3.15% sodium citrate and recovered cells counted by hemocytometer. The thorax was fixed in 10% formalin, paraffin embedded, and hematoxylin and eosin (H&E) staining was performed on 4- to 5-μm sections.

**Statistics**

The effects of genotype and treatment were assessed by two-factor, repeated-measures ANOVA followed by post hoc Bonferroni tests. A Student’s t test was used for comparisons between genotypes. Significance was set at P < 0.05. Values are means ± SEM.

**Results**

11β-HSD1 deficiency, but not 11β-HSD2 deficiency, worsens the course of experimental arthritis

Inflammatory arthritis was induced in all mice after injection of arthritogenic K/BxN serum, whether at the standard dose (Fig. 1A) or the submaximal (37% of the standard) dose (Figs. 1B and 2). However, in Hsd11b1^−/−^ mice, the onset of inflammation was earlier than in wild-type controls, irrespective of dose, and resolution was impaired, producing a greater AUC for the clinical score of inflammation (Fig. 1). Cumulative joint swelling (measured as joint thickness) induced by the stan-
dard dose of K/BxN serum was also greater in Hsd11b1−/− than in control mice (Hsd11b1+/+, 8.5 ± 0.4 mm AUC vs. controls, 6.9 ± 1.1 mm AUC, P < 0.05). Plasma corticosterone levels were elevated to a similar extent in Hsd11b1−/− and control mice 2 d after K/BxN serum injection (Hsd11b1−/−, 218 ± 61 nm vs. controls, 253 ± 39 nm), showing that inadequate hypothalamic-pituitary-adrenal (HPA) axis activation does not underlie the exacerbated acute inflammation at 2 d. However, at 21 d (when inflammation had resolved in control mice), although plasma corticosterone levels had reduced in control mice, they remained elevated in Hsd11b1−/− mice (Hsd11b1−/−, 227 ± 76 nm vs. controls, 86 ± 27 nm). This latter finding suggests the persistent activation of the HPA axis in Hsd11b1−/− mice, plausibly due to the ongoing inflammation because the negative feedback by corticosterone on the HPA axis is normal on the C57BL/6 strain background (29).

In contrast, there was no difference in the clinical score of inflammation between Hsd11b2−/− and control mice during the course of the inflammatory arthritis, with a similar AUC for both genotypes (Fig. 2). These data suggest that 11β-HSD1 limits joint inflammation in vivo, whereas 11β-HSD2 has no effect on the development or progression of K/BxN arthritis.

11β-HSD1 deficiency, but not 11β-HSD2 deficiency, worsens joint histopathology

After inflammatory arthritis (21 d after injection of K/BxN serum, when the clinical signs of inflammation had largely subsided), carpal joints from all mice showed periarticular inflammation, capsular thickening, tenosynovitis, and exostoses of distal radius and ulna and proximal metacarpals (Fig. 3). Joints of Hsd11b1−/− mice, however, had more exuberant and extensive exostoses, greater periarticular fibrosis, and, uniquely, ganglion cyst formation, suggestive of more severe inflammation (Fig. 3). In contrast, there was no histopathological difference between the joints of Hsd11b2−/− mice and controls (Fig. 3).

11β-HSD1 deficiency, but not 11β-HSD2-deficiency, results in greater inflammation during sterile peritonitis

After ip injection of thioglycollate to induce sterile peritonitis, Hsd11b1−/− mice had more inflammatory cells within the peritoneum (Fig. 4A). However, despite the increase in inflammatory cells, there was no difference in resolution of thioglycollate-induced peritonitis in Hsd11b1−/− mice (data not shown), consistent with previous data (9). In contrast, inflammatory cell number within the peritoneum was similar in Hsd11b2−/− and control mice (Fig. 4B), with no difference in resolution, suggesting that inflammation was normal in this model.

11β-HSD1 deficiency results in greater recruitment of inflammatory cells and more severe pathology in carrageenan-induced pleural inflammation

The antiinflammatory effects of 11β-HSD1 were confirmed in another model of inflammation, carrageenan-induced pleurisy, in which both inflammatory cell number and resulting pathology can be assessed within a single model. Similar to sterile peritonitis, more inflammatory cells were recovered from Hsd11b1−/− mice than control mice 4 h and 24 h after intrapleural injection of carra-
geenan (Fig. 5). Edema (assessed by weighing the collected lavages) did not differ between genotypes at either time point (data not shown). Histological assessment showed that 48 h after injection of carrageenan, inflammation in control mice was resolving yet was still in progress in Hsd11b1−/− mice, with persistence of inflammation in the visceral pleura, the presence of lymphoid aggregates (comprised of plasma cells, lymphocytes, neutrophils, and macrophages) within the lung and periesophageal mediastinum, and, uniquely in Hsd11b1−/− mice, formation of fibrous adhesions between lung lobes 48 h after initiation of pleurisy (Fig. 6). No differences in lung histology were found between untreated mice (data not shown).

**Discussion**

Mice deficient in 11β-HSD1 showed worse inflammation in three different experimental models, with impaired resolution in two. In contrast, 11β-HSD2 deficiency had no effect on inflammation in either arthritis or peritonitis. 11β-HSD1 clearly plays a role in restraining the initial inflammatory response because greater inflammatory cell number was seen in 11β-HSD1-deficient mice in both pleurisy and peritonitis, and clinical signs of arthritic inflammation were visible in these mice a full day before control mice. Why the acute response is worse in these mice is currently unclear but could be due to increased recruitment of inflammatory cells or decreased clearance. The latter is supported by our previous finding of a delay in vivo in acquisition of macrophage phagocytic capacity in Hsd11b1−/− mice (9). In both the arthritis and the pleurisy models of inflammation, Hsd11b1−/− mice showed worse pathology. This could simply reflect the greater number of inflammatory cells present during inflammation in these mice (causing greater tissue damage) or may additionally reflect an altered tissue response to inflammation. Proinflammatory cytokines induce 11β-HSD1 expression in synovial fibroblasts (13) in which locally amplified glucocorticoid action is likely to influence both the response of fibroblasts to inflammation and the local inflammatory environment that prevails during the course of arthritis. Whether a similar induction of 11β-HSD1 in pleural and lung fibroblasts dampens local proinflammatory responses and reduces inflammatory cell number in pleurisy in control mice remains to be determined but is plausible.

In the case of bone, the role of endogenous glucocorticoid metabolism here, particularly during an inflammatory response, is likely to be complex, as demonstrated by the protective effect of transgenic 11β-HSD2 expression in osteoblasts in the K/BxN serum-transfer model of arthritis (30, 31). The increased exostosis seen here in the joints of Hsd11b1−/− mice suggest altered bone turnover and/or increased bone synthesis as a response to the local proinflammatory environment [because basal bone architecture is unaltered in this model (32). The delay in the resolution of arthritis in Hsd11b1−/− mice may be due to lack of activity of this enzyme in osteoblasts or may reflect a normal response to the greater initial inflammation in Hsd11b1−/− mice.
Licorice and its active ingredients such as glycyrrhetinic acid are nonselective but potent 11β-HSD inhibitors that have long been known to exhibit antiinflammatory activity, including in rheumatoid arthritis (18). Whether this is due to increased plasma half-life of cortisol because of inhibition of renal 11β-HSD2-mediated clearance of glucocorticoids (33) or a direct intracrine effect on 11β-HSD activity at the site of inflammation is unclear. Our data do not suggest a direct effect of 11β-HSD2 deficiency on acute inflammation. Indeed, in contrast to 11β-HSD1, expression of 11β-HSD2 is down-regulated by proinflammatory cytokines (34, 35), inconsistent with any major role in the response to inflammation. Moreover, 11β-HSD2 is not expressed in mouse immune cells (11) or in human leukocytes (7). However, a caveat is raised by reports of 11β-HSD2 in synovial macrophages in rheumatoid arthritis, and it is possible that the chronic inflammatory environment with persistent disease may induce 11β-HSD2. It also remains possible that the renal phenotype of Hsd11b2−/− mice (hypertension, hypokalaemia, and hypernatraemia) compensates in some way an effect on inflammation, although it is difficult to envisage how this might come about.

Inhibition of 11β-HSD1, thus reducing intracellular glucocorticoid levels, shows promise as a drug target for treatment of metabolic disease, including type 2 diabetes mellitus (36). Our data suggest that caution should be exercised in the use of these inhibitors because they may worsen acute inflammation. Understanding how 11β-HSD1 deficiency exacerbates acute inflammation yet is protective against the low-grade inflammation associated with metabolic disease [Hsd11b1−/− mice show reduced inflammation in adipose tissue in obesity (37)] will be critical in the optimization of emerging therapies for metabolic disease. Moreover, it might facilitate development of new antiinflammatory therapies, for example, encapsulated delivery of cortisone to the site of inflammation to take advantage of local 11β-HSD1 activity to generate cortisol within the tissue in which it will be of most benefit, thus limiting the adverse metabolic effects of whole-body exposure to exogenous synthetic glucocorticoids.

Acknowledgments

We thank Ruth Andrew for help with the HPLC measurement of steroids, Katherine Miles for technical support, and Susan Harvey and Bob Morris for histology assistance.

Address all correspondence and requests for reprints to: Karen E. Chapman, Endocrinology Unit, Centre for Cardiovascular Sciences, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. E-mail: karen.chapman@ed.ac.uk.

This work was supported by Medical Research Council Project Grant G0802235 (to K.E.C., M.G., J.S.S., and J.R.S.) and Wellcome Trust Program Grants WT083184 (to J.R.S. and K.E.C.) and WT064497 (to J.S.S.). M.G. is supported by an Arthritis Research Campaign Clinician Scientist Fellowship.


References

13. Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M 2006 Differential expression, function and response to inflammatory stimuli of...


18. Davis EA, Morris DJ 1991 Medicinal uses of licorice through the millennia: the good and plenty of it. Mol Cell Endocrinol 78:1–6


